vs
Apellis Pharmaceuticals, Inc.（APLS）与KFORCE INC（KFRC）财务数据对比。点击上方公司名可切换其他公司
KFORCE INC的季度营收约是Apellis Pharmaceuticals, Inc.的1.7倍（$330.4M vs $199.9M），KFORCE INC净利率更高（2.4% vs -29.5%，领先31.9%），KFORCE INC同比增速更快（0.1% vs -5.9%），KFORCE INC自由现金流更多（$-7.4M vs $-14.3M），过去两年Apellis Pharmaceuticals, Inc.的营收复合增速更高（7.7% vs -3.7%）
Apellis Pharmaceuticals是一家临床阶段生物制药企业，专注于开发调节补体系统的靶向疗法，适应症覆盖年龄相关性黄斑变性继发地图样萎缩等眼科疾病、罕见血液病及自身免疫性疾病，核心市场为美国及欧盟地区。
Kforce Inc.是一家总部位于美国的专业人力资源服务与解决方案供应商，业务覆盖技术、财务会计、医疗保健三大核心领域，为全美各类中大型企业提供专业人才派遣、劳动力管理优化等定制服务。
APLS vs KFRC — 直观对比
营收规模更大
KFRC
是对方的1.7倍
$199.9M
营收增速更快
KFRC
高出6.0%
-5.9%
净利率更高
KFRC
高出31.9%
-29.5%
自由现金流更多
KFRC
多$6.9M
$-14.3M
两年增速更快
APLS
近两年复合增速
-3.7%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $199.9M | $330.4M |
| 净利润 | $-59.0M | $7.9M |
| 毛利率 | — | 27.3% |
| 营业利润率 | -25.6% | 3.6% |
| 净利率 | -29.5% | 2.4% |
| 营收同比 | -5.9% | 0.1% |
| 净利润同比 | -62.2% | -2.7% |
| 每股收益（稀释后） | $-0.40 | $0.46 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收APLSKFRC
| Q1 26 | — | $330.4M | ||
| Q4 25 | $199.9M | $332.0M | ||
| Q3 25 | $458.6M | $332.6M | ||
| Q2 25 | $178.5M | $334.3M | ||
| Q1 25 | $166.8M | $330.0M | ||
| Q4 24 | $212.5M | $343.8M | ||
| Q3 24 | $196.8M | $353.3M | ||
| Q2 24 | $199.7M | $356.3M |
净利润APLSKFRC
| Q1 26 | — | $7.9M | ||
| Q4 25 | $-59.0M | $5.2M | ||
| Q3 25 | $215.7M | $11.1M | ||
| Q2 25 | $-42.2M | $10.4M | ||
| Q1 25 | $-92.2M | $8.1M | ||
| Q4 24 | $-36.4M | $11.1M | ||
| Q3 24 | $-57.4M | $14.2M | ||
| Q2 24 | $-37.7M | $14.2M |
毛利率APLSKFRC
| Q1 26 | — | 27.3% | ||
| Q4 25 | — | 27.2% | ||
| Q3 25 | — | 27.7% | ||
| Q2 25 | — | 27.1% | ||
| Q1 25 | — | 26.7% | ||
| Q4 24 | — | 27.0% | ||
| Q3 24 | — | 27.9% | ||
| Q2 24 | — | 27.8% |
营业利润率APLSKFRC
| Q1 26 | — | 3.6% | ||
| Q4 25 | -25.6% | 2.6% | ||
| Q3 25 | 48.7% | 4.5% | ||
| Q2 25 | -18.6% | 4.5% | ||
| Q1 25 | -50.0% | 3.5% | ||
| Q4 24 | -12.3% | 4.5% | ||
| Q3 24 | -24.0% | 5.3% | ||
| Q2 24 | -14.7% | 5.5% |
净利率APLSKFRC
| Q1 26 | — | 2.4% | ||
| Q4 25 | -29.5% | 1.6% | ||
| Q3 25 | 47.0% | 3.3% | ||
| Q2 25 | -23.6% | 3.1% | ||
| Q1 25 | -55.3% | 2.5% | ||
| Q4 24 | -17.1% | 3.2% | ||
| Q3 24 | -29.2% | 4.0% | ||
| Q2 24 | -18.9% | 4.0% |
每股收益（稀释后）APLSKFRC
| Q1 26 | — | $0.46 | ||
| Q4 25 | $-0.40 | $0.29 | ||
| Q3 25 | $1.67 | $0.63 | ||
| Q2 25 | $-0.33 | $0.59 | ||
| Q1 25 | $-0.74 | $0.45 | ||
| Q4 24 | $-0.30 | $0.60 | ||
| Q3 24 | $-0.46 | $0.75 | ||
| Q2 24 | $-0.30 | $0.75 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $466.2M | $1.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $370.1M | $117.4M |
| 总资产 | $1.1B | $384.8M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资APLSKFRC
| Q1 26 | — | $1.3M | ||
| Q4 25 | $466.2M | $2.1M | ||
| Q3 25 | $479.2M | $1.3M | ||
| Q2 25 | $370.0M | $2.5M | ||
| Q1 25 | $358.4M | $444.0K | ||
| Q4 24 | $411.3M | $349.0K | ||
| Q3 24 | $396.9M | $127.0K | ||
| Q2 24 | $360.1M | $110.0K |
股东权益APLSKFRC
| Q1 26 | — | $117.4M | ||
| Q4 25 | $370.1M | $124.6M | ||
| Q3 25 | $401.2M | $132.1M | ||
| Q2 25 | $156.3M | $134.4M | ||
| Q1 25 | $164.2M | $138.0M | ||
| Q4 24 | $228.5M | $154.6M | ||
| Q3 24 | $237.1M | $167.4M | ||
| Q2 24 | $264.3M | $166.6M |
总资产APLSKFRC
| Q1 26 | — | $384.8M | ||
| Q4 25 | $1.1B | $365.6M | ||
| Q3 25 | $1.1B | $374.2M | ||
| Q2 25 | $821.4M | $373.6M | ||
| Q1 25 | $807.3M | $368.2M | ||
| Q4 24 | $885.1M | $357.8M | ||
| Q3 24 | $901.9M | $369.9M | ||
| Q2 24 | $904.5M | $362.7M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-14.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-14.3M | $-7.4M |
| 自由现金流率自由现金流/营收 | -7.1% | -2.2% |
| 资本支出强度资本支出/营收 | 0.1% | 1.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $45.0M | $43.3M |
8季度趋势，按日历期对齐
经营现金流APLSKFRC
| Q1 26 | — | — | ||
| Q4 25 | $-14.2M | $19.7M | ||
| Q3 25 | $108.5M | $23.3M | ||
| Q2 25 | $4.4M | $18.4M | ||
| Q1 25 | $-53.4M | $249.0K | ||
| Q4 24 | $19.4M | $21.8M | ||
| Q3 24 | $34.1M | $31.0M | ||
| Q2 24 | $-8.3M | $20.9M |
自由现金流APLSKFRC
| Q1 26 | — | $-7.4M | ||
| Q4 25 | $-14.3M | $16.7M | ||
| Q3 25 | $108.3M | $19.8M | ||
| Q2 25 | $4.4M | $14.2M | ||
| Q1 25 | $-53.4M | $-3.9M | ||
| Q4 24 | $19.3M | $20.9M | ||
| Q3 24 | — | $27.5M | ||
| Q2 24 | $-8.4M | $17.8M |
自由现金流率APLSKFRC
| Q1 26 | — | -2.2% | ||
| Q4 25 | -7.1% | 5.0% | ||
| Q3 25 | 23.6% | 6.0% | ||
| Q2 25 | 2.5% | 4.3% | ||
| Q1 25 | -32.0% | -1.2% | ||
| Q4 24 | 9.1% | 6.1% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | -4.2% | 5.0% |
资本支出强度APLSKFRC
| Q1 26 | — | 1.0% | ||
| Q4 25 | 0.1% | 0.9% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 1.2% | ||
| Q1 25 | 0.0% | 1.3% | ||
| Q4 24 | 0.0% | 0.3% | ||
| Q3 24 | 0.0% | 1.0% | ||
| Q2 24 | 0.0% | 0.9% |
现金转化率APLSKFRC
| Q1 26 | — | — | ||
| Q4 25 | — | 3.82× | ||
| Q3 25 | 0.50× | 2.11× | ||
| Q2 25 | — | 1.76× | ||
| Q1 25 | — | 0.03× | ||
| Q4 24 | — | 1.97× | ||
| Q3 24 | — | 2.18× | ||
| Q2 24 | — | 1.48× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
APLS
| Syfovre | $155.2M | 78% |
| Empaveli Pegcetacoplan | $35.1M | 18% |
| Licensing And Other Revenue | $9.6M | 5% |
KFRC
暂无分部数据
